Open AccessThe Co-Expression of Kallikrein 5 and Kallikrein 7 Associates with Poor Survival in Non-HPV Oral Squamous-Cell Carcinoma
Author(s) -
Frank K.J. Leusink,
P. J. van Diest,
Michael Frank,
Roel Broekhuizen,
W.W. Braunius,
Sander R. van Hooff,
Stefan M. Willems,
R. Koole
Publication year - 2015
Publication title -
pathobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.941
H-Index - 53
eISSN - 1423-0291
pISSN - 1015-2008
DOI - 10.1159/000381904
Subject(s) - kallikrein , medicine , oncology , cancer research , cancer , biology , biochemistry , enzyme
Oral squamous-cell carcinoma (OSCC) still has a poor prognosis. Lymph node metastasis (LNM) is a major determinant of treatment decisions and prognosis. Serine protease inhibitor Kazal-type 5 (SPINK5) is the inhibitor of kallikrein 5 (KLK5) and KLK7. SPINK5, KLK5 and KLK7 are three of the genes of a recently validated LNM-predicting gene expression profile in OSCC. This study evaluates their clinicopathological role and value as biomarkers in OSCC.